Navigation Links
Company's Partner Completes Trial Production of a New Antiviral Medicine
Date:10/15/2007

HANGZHOU, China, Oct. 15 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that its partner, Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") has successfully completed its trial production of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV up to 90% only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33. The sample product is available for distributors now and the commercial product will be available next month.

HPV infection is common across all races and socio-economic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% of people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression.

According to the agreement reached with Soonfast in June this year, China Biopharma has the right to distribute this new all-natural antiviral medicine in overseas market. The successful trial production has now quickened some approval process for China Biopharma to launch commercial sales on overseas market including Europe and the United States. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and USA so as to obtain approval necessary for selling this medicine as an over-the-counter drug. The company believes this new medicine would bring in significant revenue and profit in the near future once it is successfully introduced into the market.


'/>"/>

SOURCE China Biopharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Berbees success is based on companys history and culture
2. APIs New Name Reflects Companys Current Direction
3. Detecting Your Companys Early Trouble Signs
4. Jellyfish partners for sales tracking technology
5. GE Healthcare partners with UNC on breast cancer imaging research
6. Manufacturing partnership will move into biotech and biomedical spaces
7. Fergus joins Baird Venture Partners, Caden Bio
8. Avolte Venture Partners reaches capital goal
9. NimbleGen partners with UK biotech firm
10. Big pharma seeks Wisconsin biotech partnerships
11. Thompson in partnership to build ethanol plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 The North American chromatography systems ... from 2014 to 2019. Based on geography, this market has ... and Mexico . The U.S. accounted for ... . The major factors driving the growth of chromatography systems ... industries are the prime users of chromatography techniques. ...
(Date:4/21/2015)... WORTH, Texas , April 21, 2015 ... to grow from $313.0 million in 2014 to $605.1 million ... period under consideration. Browse through the TOC ... for an in-depth analysis of the industry trends and ... http://www.micromarketmonitor.com/market/north-america-bio-stimulants-6850160039.html Early buyers ...
(Date:4/21/2015)... , April 21, 2015  Scientists from the ... research organization, published a paper today outlining new ... microalgae called diatoms. The researchers, led by first ... author Philip Weyman , Ph.D., conclude that ... understanding of diatom genetics and thus facilitate advances ...
(Date:4/21/2015)... Invetech , a global leader ... contract manufacturing, and  NanoCellect Biomedical, a company ... sorting technology for life science researchers, today announced ... platform. Headquartered in San ... microchip-based cell sorting technology. NanoCellect,s flow cytometry platform ...
Breaking Biology Technology:North American Chromatography systems Market by Types, & by End-Users - Forecast to 2019 2North American Chromatography systems Market by Types, & by End-Users - Forecast to 2019 3North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3
... New York on Monday, September 10th, SAN ... biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment ... President and Chief Executive Officer, will present at,the ... p.m. Eastern,time on Monday, September 10, 2007. The ...
... CDC to Ensure US,s Preparedness ... Emergency, CAMBRIDGE, England and CAMBRIDGE, Massachusetts, September ... company, announced today that the US Food and ... Vaccine, Live) vaccine,for protection against smallpox. The vaccine ...
... announced,today that one year findings from the ... net clinical benefit for patients with acute,ST-segment ... Heparin (UFH). The ExTRACT-TIMI 25 and ... sessions at the European Society of Cardiology ...
Cached Biology Technology:FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 2FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 3FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 4FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 5New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... weapon in the arsenal against cancer: Nanoparticles that identify, ... cells alone. Led by Carl Batt, the Liberty ... nanoparticles shaped something like a dumbbell made ... They then attached antibodies, which target a molecule found ...
... of God and the nature of religion, two distinguished ... in evolutionary biology with a focus on brain science, ... Tiger and pioneering neuroscientist Michael McGuire elucidate perennial questions ... arise? What is its source? And why does every ...
... breakthrough treatments for the most common cancers could soon come ... At the ESMO Conference on Sarcoma and GIST, to ... 2010, researchers and some of the world,s leading experts will ... found in muscle, blood vessels, deep skin tissues, nerves and ...
Cached Biology News:Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2Which came first: Religion or the brain? 2Spotlight on rare tumors in hunt for new cancer treatments 2
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
LabFax: Immunochemistry...
Biology Products: